Nurix Therapeutics is a clinical-stage biopharmaceutical company developing medicines that harness targeted protein degradation to remove disease-causing proteins. Its pipeline focuses on oncology and immune-mediated diseases using proprietary degrader and E3 ligase platforms. The company partners with larger pharmaceutical firms while advancing its own candidates for patients underserved by conventional small-molecule or antibody approaches.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 44.1 | — | -43.5 | — |
| Q3 2025 | 7.9 | — | -86.4 | — |
| Q4 2025 | 13.6 | — | -78.2 | — |
| Q1 2026 | 6.3 | — | -87.2 | — |
| Q2 2026 | 9 | -79.5% | -89.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Dyne Therapeutics, Inc. (DYN), Liberty Global Ltd. (LBTYA), Digi International Inc. (DGII), Astronics Corporation (ATRO), NBT Bancorp Inc. (NBTB), Central Garden & Pet Company (CENT)